About Sudeep Pharma Ltd.
let’s dicscuss about Sudeep Pharma IPO.
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.
The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specialiThe company is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries, dedicated to contributing to the global healthcare ecosystem. The company leverages in-house developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending to drive innovation in operations. The company has established a presence in both domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. According to the F&S Report, the company is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual available manufacturing capacity of 72,246 metric tons as of June 30, 2025.zing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium
The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors
The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Product Portfolio:
- Pharmaceutical, Food and Nutrition Business
- Specialty Ingredients Business
- Triturates
As of December 31, 2024, the company had 704 permanent employees.
Competitve Strengths:
- The company is a leading manufacturer of pharmaceutical, food, nutrition, and specialty ingredients with over 100 products and combined annual manufacturing capacity of 72,246 MT as of June 30, 2025.
- The company serves over 1,100 customers across 100 countries including 14 Fortune 500 companies, with average tenure of 7.08 years with top five customers and 83.17% repeat business.
- Well-equipped and regulatory compliant Manufacturing Facilities
- Strong research and development capabilities
Sudeep Pharma IPO Details
| IPO Date | November 21, 2025 to November 25, 2025 |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Issue Price Band | ₹563 to ₹593 per share |
| Lot Size | 25 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 1,50,92,750 shares (aggregating up to ₹895.00 Cr) |
| Fresh Issue | 16,02,024 shares (aggregating up to ₹95.00 Cr) |
| Offer for Sale | 1,34,90,726 shares of ₹1 (aggregating up to ₹800.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 11,13,46,602 shares |
| Share Holding Post Issue | 11,29,48,626 shares |
udeep Pharma IPO Timeline (Tentative Schedule)
Sudeep Pharma IPO opens on November 21, 2025, and closes on November 25, 2025.
| IPO Open Date | Fri, Nov 21, 2025 |
| IPO Close Date | Tue, Nov 25, 2025 |
| Tentative Allotment | Wed, Nov 26, 2025 |
| Initiation of Refunds | Thu, Nov 27, 2025 |
| Credit of Shares to Demat | Thu, Nov 27, 2025 |
| Tentative Listing Date | Fri, Nov 28, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Tue, Nov 25, 2025 |
Sudeep Pharma IPO Reservation
Sudeep Pharma IPO offers total 1,50,92,750 shares. Out of which 75,46,376 (50.00%) allocated to QIB, 30,18,553 (20.00%) allocated to QIB (Ex- Anchor), 22,63,912 (15.00%) allocated to NII 52,82,462 (35.00%) allocated to RII and 45,27,823 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Retail Shares Offered | 52,82,462 (35.00%) | |
| Total Shares Offered | 1,50,92,750 (100.00%) |
Sudeep Pharma IPO Lot Size
Lot size has been defined here for retailer upto max of 2 lakhs rupees.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹1,92,725 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| S-HNI (Max) | 67 | 1,675 | ₹9,93,275 |
| B-HNI (Min) | 68 | 1,700 | ₹10,08,100 |
Sudeep Pharma IPO Promoter Holding
Promoter holding has beed shown pre and post IPO.
| Promoter Holding Pre Issue | 89.37% |
| Promoter Holding Post Issue | 76.15% |
Key Performance Indicator (KPI)
KPI as of Mon, Mar 31, 2025.
| KPI | Values |
|---|---|
| Debt/Equity | 0.20 |
| RoNW | 27.88% |
| PAT Margin | 27.63% |
| EBITDA Margin | 39.70% |
| Price to Book Value | 12.93 |
| Market Capitalization | ₹6,697.85 Cr. |
Write view : IPO comes with a high valuation , if wish to subscribe better to be done after listing. By the way disclaimer is that I a not a SEBI registered Research Analyst. View are for knowledge purpose only.
Also read :